Refine
Has Fulltext
- yes (11)
Is part of the Bibliography
- yes (11)
Document Type
- Journal article (10)
- Doctoral Thesis (1)
Language
- English (11)
Keywords
- Alzheimers disease (1)
- Amyotrophic-lateral-sclerosis (1)
- Axon degeneration (1)
- Axonal transport (1)
- CCL3 (1)
- CCL4 (1)
- CCL5 (1)
- Chlamydia trachomatis (1)
- HDBSCAN (1)
- Halcyon (1)
Institute
- Theodor-Boveri-Institut für Biowissenschaften (6)
- Rudolf-Virchow-Zentrum (4)
- Medizinische Klinik und Poliklinik II (3)
- Klinik und Poliklinik für Strahlentherapie (2)
- Center for Computational and Theoretical Biology (1)
- Frauenklinik und Poliklinik (1)
- Institut für Anatomie und Zellbiologie (1)
- Institut für Hygiene und Mikrobiologie (1)
- Institut für Klinische Neurobiologie (1)
- Institut für Virologie und Immunbiologie (1)
Immune checkpoint blockade therapy is beneficial and even curative for some cancer patients. However, the majority don’t respond to immune therapy. Across different tumor types, pre-existing T cell infiltrates predict response to checkpoint-based immunotherapy. Based on in vitro pharmacological studies, mouse models and analyses of human melanoma patients, we show that the cytokine GDF-15 impairs LFA-1/β2-integrin-mediated adhesion of T cells to activated endothelial cells, which is a pre-requisite of T cell extravasation. In melanoma patients, GDF-15 serum levels strongly correlate with failure of PD-1-based immune checkpoint blockade therapy. Neutralization of GDF-15 improves both T cell trafficking and therapy efficiency in murine tumor models. Thus GDF-15, beside its known role in cancer-related anorexia and cachexia, emerges as a regulator of T cell extravasation into the tumor microenvironment, which provides an even stronger rationale for therapeutic anti-GDF-15 antibody development.